



# Aarti Drugs Limited

**Manufacturers of : Bulk Drugs & Chemicals**

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax: 022-2407 3462 / 2407 0144  
Email: [audit@aartidrugs.com](mailto:audit@aartidrugs.com)  
website: [www.aartidrugs.com](http://www.aartidrugs.com)  
CIN No.: L37060MH1984PLC055433

Ref. No: ADL/SE-2M/2016

Date : 5<sup>th</sup> February, 2016

To,  
Listing/Compliance Department  
**BSE LTD.**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001.  
**BSE CODE –524348**

To,  
Listing/Compliance Department  
**National Stock Exchange of  
India Limited**

“Exchange Plaza”, Plot No. C/1,  
G Block Bandra-Kurla Complex,  
Bandra (E), Mumbai – 400 051.  
**NSE CODE:AARTIDRUGS**

Dear Sir/Madam,

Please find enclosed herewith copy of press release issued by the company on 5<sup>th</sup> February, 2016.

Kindly take the note of the above.

Thanking You

Yours faithfully,  
For **AARTI DRUGS LIMITED**

**HARSHIT M. SAVLA**  
**JT. MANAGING DIRECTOR**

Encl: as above.



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax: 022-2407 3462 / 2407 0144  
Email: audit@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.: L37060MH1984PLC055433

## Press release for Dec' 2015:

Macroeconomic factors that are unfavourable to global trade, continues to impact the export sales and indirectly the domestic sales, which are related to formulation exports. In spite of this, company has shown good growth in the domestic markets.

Consolidated EBITDA for the period ended Dec' 15 is 129.93 crores, up by 3.07%, indicating stable operational efficiency. Profit before tax has gone down on account of higher depreciation and interest costs, due to commissioning of various expansion projects. Company has taken swift action to reduce inventory levels to be adaptable to face current industry challenges.

Expansion project of anti- diarrheal product went live in Dec'15 quarter which will give boost to sales in future. Company seeks to get regulatory approvals for its new anti-biotic facility, which will give impetus to topline in near future. Company is actively seeking for re-inspection from USFDA authorities, to restart its USA business.

For AARTI DRUGS LIMITED

HARSHIT M. SAVLA  
JT. MANAGING DIRECTOR